Showing 51-60 of 3896 results for "".
The Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Graduating from Dermatology Residency into the COVID-19 Job Market
https://practicaldermatology.com/youngmd-connect/resident-resource-center/graduating-from-dermatology-residency-into-the-covid-19-job-market/23437/Third-year dermatology residents are graduating into an uncertain job market. What does the future hold?Journal Club: Tapinarof Cream in Pediatric Patients
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-tapinarof-cream-in-pediatric-patients/32399/Practical Dermatology Editorial Board member Peter Lio, MD, speaks with Mona Shahriari, MD, about the Journal of Dermatology article "A phase 2, randomized, double-blind, vehicle-controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis," and the general importance ofJournal Club: Dupilumab and Atopic March
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseJAK Inhibitors Make the Cut for Alopecia Areata
https://practicaldermatology.com/topics/hair-nails/jak-inhibitors-make-the-cut-for-alopecia-areata/23935/JAK inhibitor approvals increase the opportunity for patients with alopecia areata to experience “life-changing” results.DermWireTV: New Data Presented for Atopic Dermatitis and Prurigo Nodularis Candidates at AAD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-data-presented-for-atopic-dermatitis-and-prurigo-nodularis-candidates-at-aad/24127/In this episode of DermWireTV, a phase 3 study finds roflumilast cream is associated with significantly improved atopic dermatitis in children; first-of-its-kind research suggests that eczema treatment lebrikizumab shows efficacy and safety in patients with skin of color; and new data reveals oral JLupus erythematosus tumidus vs Jessner's lymphocytic infiltrate of the Skin
https://practicaldermatology.com/topics/general-topics/lupus-erythematosus-tumidus-vs-jessners-lymphocytic-infiltrate-of-the-skin/21686/A systematic comparison of clinical and histologic characteristics.Maximizing Valuation and Outcomes for Practice Owners: A Conversation with Dana Jacoby
https://practicaldermatology.com/topics/practice-management/maximizing-valuation-and-outcomes-for-practice-owners-a-conversation-with-dana-jacoby/29889/Contributor Clint Bundy recently interviewed Dana Jacoby, President and CEO of Vector Medical Group, an operational and strategic consulting firm focused on the healthcare sector, to discuss building value in a dermatology and aesthetics practice and optimal ways to achieve full value for that businHow to Get Job Seekers to Apply to Your Job
https://practicaldermatology.com/topics/practice-management/how-to-get-job-seekers-to-apply-to-your-job/23152/Learn the secrets to getting qualified physicians to apply to your job.